Laboratory Evaluation of Pediatric Inflammatory Bowel Disease

  • Jennifer Strople
  • Benjamin D. Gold


Inflammatory Bowel Disease Irritable Bowel Syndrome Intestinal Inflammation Crohn Disease Mycobacterium Avium Subspecies Paratuberculosis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Sabery N, Bass D. Use of serologic markers as a screening tool in inflammatory bowel disease compared with elevated erythrocyte sedimentation rate and anemia. Pediatrics 2007;119:e193–9.PubMedCrossRefGoogle Scholar
  2. 2.
    Hait E, Bousvaros A, Grand R. Pediatric inflammatory bowel disease: what children can teach adults. Inflamm Bowel Dis 2005;11:519–27.PubMedCrossRefGoogle Scholar
  3. 3.
    Auvin S, Molinie F, Gower-Rousseau C et al. Incidence, clinical presentation and location at diagnosis of pediatric inflammatory bowel disease: a prospective population-based study in northern France (1988–1999). J Pediatr Gastroenterol Nutr 2005;41:49–55.PubMedCrossRefGoogle Scholar
  4. 4.
    Oliva-Hemker M, Fiocchi C. Etiopathogenesis of inflammatory bowel disease: the importance of the pediatric perspective. Inflamm Bowel Dis 2002;8:112–28.PubMedCrossRefGoogle Scholar
  5. 5.
    Dubinsky MC, Ofman JJ, Urman M, Targan SR, Seidman EG. Clinical utility of serodiagnostic testing in suspected pediatric inflammatory bowel disease. Am J Gastroenterol 2001;96:758–65.PubMedCrossRefGoogle Scholar
  6. 6.
    Hyams J, Markowitz J, Otley A et al. Evaluation of the pediatric crohn disease activity index: a prospective multicenter experience. J Pediatr Gastroenterol Nutr 2005;41:416–21.PubMedCrossRefGoogle Scholar
  7. 7.
    Hyams JS, Ferry GD, Mandel FS et al. Development and validation of a pediatric Crohn’s disease activity index. J Pediatr Gastroenterol Nutr 1991;12:439–47.PubMedGoogle Scholar
  8. 8.
    Griffiths AM, Otley AR, Hyams J et al. A review of activity indices and end points for clinical trials in children with Crohn’s disease. Inflamm Bowel Dis 2005;11:185–96.PubMedCrossRefGoogle Scholar
  9. 9.
    Mylonaki M, Langmead L, Pantes A, Johnson F, Rampton DS. Enteric infection in relapse of inflammatory bowel disease: importance of microbiological examination of stool. Eur J Gastroenterol Hepatol 2004;16:775–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Roy CN, Weinstein DA, Andrews NC. 2002 t E. Mead Johnson Award for Research in Pediatrics Lecture: the molecular biology of the anemia of chronic disease: a hypothesis. Pediatr Res 2003;53:507–12.CrossRefGoogle Scholar
  11. 11.
    Koutroubakis IE, Karmiris K, Kouroumalis EA. Treatment of anaemia in inflammatory bowel disease. Aliment Pharmacol Ther 2006;23:1273–4; author reply 1274–5.PubMedCrossRefGoogle Scholar
  12. 12.
    Wells CW, Lewis S, Barton JR, Corbett S. Effects of changes in hemoglobin level on quality of life and cognitive function in inflammatory bowel disease patients. Inflamm Bowel Dis 2006;12:123–30.PubMedCrossRefGoogle Scholar
  13. 13.
    Thayu M, Leonard MG, Baldassano RN, Mamula P. Prevalence of Anemia in Incident Pediatric Crohn Disease. J Pediatr Gastroenterol Nutr 2005;41:547.Google Scholar
  14. 14.
    Thayu M, Mamula P. Treatment of iron deficiency anemia in pediatric inflammatory bowel disease. Curr Treat Options Gastroenterol 2005;8:411–7.PubMedCrossRefGoogle Scholar
  15. 15.
    Gasche C, Lomer MC, Cavill I, Weiss G. Iron, anaemia, and inflammatory bowel diseases. Gut 2004;53:1190–7.PubMedCrossRefGoogle Scholar
  16. 16.
    Wilson A, Reyes E, Ofman J. Prevalence and outcomes of anemia in inflammatory bowel disease: a systematic review of the literature. Am J Med 2004;116 Suppl 7A:44S–49S.PubMedCrossRefGoogle Scholar
  17. 17.
    Beattie RM, Walker-Smith JA, Murch SH. Indications for investigation of chronic gastrointestinal symptoms. Arch Dis Child 1995;73:354–5.PubMedGoogle Scholar
  18. 18.
    Burbige EJ, Huang SH, Bayless TM. Clinical manifestations of Crohn’s disease in children and adolescents. Pediatrics 1975;55:866–71.PubMedGoogle Scholar
  19. 19.
    Dyer NH, Child JA, Mollin DL, Dawson AM. Anaemia in Crohn’s disease. Q J Med 1972;41:419–36.PubMedGoogle Scholar
  20. 20.
    Thomson AB, Brust R, Ali MA, Mant MJ, Valberg LS. Iron deficiency in inflammatory bowel disease. Diagnostic efficacy of serum ferritin. Am J Dig Dis 1978;23:705–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Tsitsika A, Stamoulakatou A, Kafritsa Y et al. Erythropoietin levels in children and adolescents with inflammatory bowel disease. J Pediatr Hematol Oncol 2005;27:93–6.PubMedCrossRefGoogle Scholar
  22. 22.
    Margetic S, Topic E, Ruzic DF, Kvaternik M. Soluble transferrin receptor and transferrin receptor-ferritin index in iron deficiency anemia and anemia in rheumatoid arthritis. Clin Chem Lab Med 2005;43:326–31.PubMedCrossRefGoogle Scholar
  23. 23.
    Markovic M, Majkic-Singh N, Subota V. Usefulness of soluble transferrin receptor and ferritin in iron deficiency and chronic disease. Scand J Clin Lab Invest 2005;65:571–6.PubMedCrossRefGoogle Scholar
  24. 24.
    Baillie FJ, Morrison AE, Fergus I. Soluble transferrin receptor: a discriminating assay for iron deficiency. Clin Lab Haematol 2003;25:353–7.PubMedCrossRefGoogle Scholar
  25. 25.
    Matsumoto T. Platelets in inflammatory bowel disease. J Gastroenterol 2006;41:91–2.PubMedCrossRefGoogle Scholar
  26. 26.
    Danese S, Scaldaferri F, Papa A et al. Platelets: new players in the mucosal scenario of inflammatory bowel disease. Eur Rev Med Pharmacol Sci 2004;8:193–8.PubMedGoogle Scholar
  27. 27.
    Morowitz DA, Allen LW, Kirsner JB. Thrombocytosis in chronic inflammatory bowel disease. Ann Intern Med 1968;68:1013–21.PubMedGoogle Scholar
  28. 28.
    Vowinkel T, Anthoni C, Wood KC, et al. CD40-CD40 ligand mediates the recruitment of leukocytes and platelets in the inflamed murine colon. Gastroenterology 2007;132:955–65.PubMedCrossRefGoogle Scholar
  29. 29.
    Kayo S, Ikura Y, Suekane T et al. Close association between activated platelets and neutrophils in the active phase of ulcerative colitis in humans. Inflamm Bowel Dis 2006;12:727–35.PubMedCrossRefGoogle Scholar
  30. 30.
    Harries AD, Beeching NJ, Rogerson SJ, Nye FJ. The platelet count as a simple measure to distinguish inflammatory bowel disease from infective diarrhoea. J Infect 1991;22:247–50.PubMedCrossRefGoogle Scholar
  31. 31.
    Lam A, Borda IT, Inwood MJ, Thomson S. Coagulation studies in ulcerative colitis and Crohn’s disease. Gastroenterology 1975;68:245–51.PubMedGoogle Scholar
  32. 32.
    Talstad I, Rootwelt K, Gjone E. Thrombocytosis in ulcerative colitis and Crohn’s disease. Scand J Gastroenterol 1973;8:135–8.PubMedGoogle Scholar
  33. 33.
    Cabrera-Abreu JC, Davies P, Matek Z, Murphy MS. Performance of blood tests in diagnosis of inflammatory bowel disease in a specialist clinic. Arch Dis Child 2004;89:69–71.PubMedGoogle Scholar
  34. 34.
    Desai D, Faubion WA, Sandborn WJ. Review article: biological activity markers in inflammatory bowel disease. Aliment Pharmacol Ther 2007;25:247–55.PubMedCrossRefGoogle Scholar
  35. 35.
    Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut 2006;55:426–31.Google Scholar
  36. 36.
    Shine B, Berghouse L, Jones JE, Landon J. C-reactive protein as an aid in the differentiation of functional and inflammatory bowel disorders. Clin Chim Acta 1985;148:105–9.PubMedCrossRefGoogle Scholar
  37. 37.
    Sachar DB, Smith H, Chan S, Cohen LB, Lichtiger S, Messer J. Erythrocytic sedimentation rate as a measure of clinical activity in inflammatory bowel disease. J Clin Gastroenterol 1986;8:647–50.PubMedCrossRefGoogle Scholar
  38. 38.
    Solem CA, Loftus EV, Jr., Tremaine WJ, Harmsen WS, Zinsmeister AR, Sandborn WJ. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis 2005;11:707–12.PubMedCrossRefGoogle Scholar
  39. 39.
    Fagan EA, Dyck RF, Maton PN et al. Serum levels of C-reactive protein in Crohn’s disease and ulcerative colitis. Eur J Clin Invest 1982;12:351–9.PubMedCrossRefGoogle Scholar
  40. 40.
    Saverymuttu SH, Hodgson HJ, Chadwick VS, Pepys MB. Differing acute phase responses in Crohn’s disease and ulcerative colitis. Gut 1986;27:809–13.PubMedCrossRefGoogle Scholar
  41. 41.
    Poullis AP, Zar S, Sundaram KK et al. A new, highly sensitive assay for C-reactive protein can aid the differentiation of inflammatory bowel disorders from constipation- and diarrhoea-predominant functional bowel disorders. Eur J Gastroenterol Hepatol 2002;14:409–12.PubMedCrossRefGoogle Scholar
  42. 42.
    Maudgal DP, Ang L, Patel S, Bland JM, Maxwell JD. Nutritional assessment in patients with chronic gastrointestinal symptoms: comparison of functional and organic disorders. Hum Nutr Clin Nutr 1985;39:203–12.PubMedGoogle Scholar
  43. 43.
    Kane W, Miller K, Sharp HL. Inflammatory bowel disease presenting as liver disease during childhood. J Pediatr 1980;97:775–8.PubMedCrossRefGoogle Scholar
  44. 44.
    Gupta N, Cohen SA, Bostrom AG et al. Risk factors for initial surgery in pediatric patients with Crohn’s disease. Gastroenterology 2006;130:1069–77.PubMedCrossRefGoogle Scholar
  45. 45.
    Ferrante M, Penninckx F, De Hertogh G et al. Protein-losing enteropathy in Crohn’s disease. Acta Gastroenterol Belg 2006;69:384–9.PubMedGoogle Scholar
  46. 46.
    Semeao EJ, Jawad AF, Stouffer NO, Zemel BS, Piccoli DA, Stallings VA. Risk factors for low bone mineral density in children and young adults with Crohn’s disease. J Pediatr 1999;135:593–600.PubMedCrossRefGoogle Scholar
  47. 47.
    Thomas DW, Sinatra FR. Screening laboratory tests for Crohn’s disease. West J Med 1989;150:163–4.PubMedGoogle Scholar
  48. 48.
    Mendes FD, Levy C, Enders FB, Loftus EV, Jr., Angulo P, Lindor KD. Abnormal hepatic biochemistries in patients with inflammatory bowel disease. Am J Gastroenterol 2007;102:344–50.PubMedCrossRefGoogle Scholar
  49. 49.
    Broome U, Glaumann H, Hellers G, Nilsson B, Sorstad J, Hultcrantz R. Liver disease in ulcerative colitis: an epidemiological and follow up study in the county of Stockholm. Gut 1994;35:84–9.PubMedCrossRefGoogle Scholar
  50. 50.
    Feldstein AE, Perrault J, El-Youssif M, Lindor KD, Freese DK, Angulo P. Primary sclerosing cholangitis in children: a long-term follow-up study. Hepatology 2003;38:210–7.PubMedCrossRefGoogle Scholar
  51. 51.
    Hyams JS. Extraintestinal manifestations of inflammatory bowel disease in children. J Pediatr Gastroenterol Nutr 1994;19:17–21.Google Scholar
  52. 52.
    Wilschanski M, Chait P, Wade JA et al. Primary sclerosing cholangitis in 32 children: clinical, laboratory, and radiographic features, with survival analysis. Hepatology 1995;22:1415–22.PubMedGoogle Scholar
  53. 53.
    Ridder RM, Kreth HW, Kiss E, Grone HJ, Gordjani N. Membranous nephropathy associated with familial chronic ulcerative colitis in a 12-year-old girl. Pediatr Nephrol 2005;20:1349–51.PubMedCrossRefGoogle Scholar
  54. 54.
    Siveke JT, Egert J, Sitter T et al. 5-ASA therapy and renal function in inflammatory bowel disease. Am J Gastroenterol 2005;100:501.PubMedCrossRefGoogle Scholar
  55. 55.
    Van Staa TP, Travis S, Leufkens HG, Logan RF. 5-aminosalicylic acids and the risk of renal disease: a large British epidemiologic study. Gastroenterology 2004;126:1733–9.PubMedCrossRefGoogle Scholar
  56. 56.
    Margetts PJ, Churchill DN, Alexopoulou I. Interstitial nephritis in patients with inflammatory bowel disease treated with mesalamine. J Clin Gastroenterol 2001;32:176–8.PubMedCrossRefGoogle Scholar
  57. 57.
    De Broe ME, Stolear JC, Nouwen EJ, Elseviers MM. 5-Aminosalicylic acid (5-ASA) and chronic tubulointerstitial nephritis in patients with chronic inflammatory bowel disease: is there a link? Nephrol Dial Transplant 1997;12:1839–41.Google Scholar
  58. 58.
    Izzedine H, Simon J, Piette AM et al. Primary chronic interstitial nephritis in Crohn’s disease. Gastroenterology 2002;123:1436–40.PubMedCrossRefGoogle Scholar
  59. 59.
    Canani RB, de Horatio LT, Terrin G et al. Combined use of noninvasive tests is useful in the initial diagnostic approach to a child with suspected inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2006;42:9–15.PubMedCrossRefGoogle Scholar
  60. 60.
    Olives JP, Breton A, Hugot JP et al. Antineutrophil cytoplasmic antibodies in children with inflammatory bowel disease: prevalence and diagnostic value. J Pediatr Gastroenterol Nutr 1997;25:142–8.PubMedCrossRefGoogle Scholar
  61. 61.
    Ruemmele FM, Targan SR, Levy G, Dubinsky M, Braun J, Seidman EG. Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease. Gastroenterology 1998;115:822–9.PubMedCrossRefGoogle Scholar
  62. 62.
    Dubinsky MC, Johanson JF, Seidman EG, Ofman JJ. Suspected inflammatory bowel disease–the clinical and economic impact of competing diagnostic strategies. Am J Gastroenterol 2002;97:2333–42.PubMedGoogle Scholar
  63. 63.
    Hoffenberg EJ, Fidanza S, Sauaia A. Serologic testing for inflammatory bowel disease. J Pediatr 1999;134:447–52.PubMedCrossRefGoogle Scholar
  64. 64.
    Gupta SK, Fitzgerald JF, Croffie JM, Pfefferkorn MD, Molleston JP, Corkins MR. Comparison of serological markers of inflammatory bowel disease with clinical diagnosis in children. Inflamm Bowel Dis 2004;10:240–4.PubMedCrossRefGoogle Scholar
  65. 65.
    Zholudev A, Zurakowski D, Young W, Leichtner A, Bousvaros A. Serologic testing with ANCA, ASCA, and anti-OmpC in children and young adults with Crohn’s disease and ulcerative colitis: diagnostic value and correlation with disease phenotype. Am J Gastroenterol 2004;99:2235–41.PubMedCrossRefGoogle Scholar
  66. 66.
    Elitsur Y, Lawrence Z, Tolaymat N. The diagnostic accuracy of serologic markers in children with IBD: the West Virginia experience. J Clin Gastroenterol 2005;39:670–3.PubMedCrossRefGoogle Scholar
  67. 67.
    Khan K, Schwarzenberg SJ, Sharp H, Greenwood D, Weisdorf-Schindele S. Role of serology and routine laboratory tests in childhood inflammatory bowel disease. Inflamm Bowel Dis 2002;8:325–9.PubMedCrossRefGoogle Scholar
  68. 68.
    Young Y, Abreu MT. Advances in the pathogenesis of inflammatory bowel disease. Curr Gastroenterol Rep 2006;8:470–7.PubMedCrossRefGoogle Scholar
  69. 69.
    Papadakis KA, Yang H, Ippoliti A et al. Anti-flagellin (CBir1) phenotypic and genetic Crohn’s disease associations. Inflamm Bowel Dis 2007;13:524–30.PubMedCrossRefGoogle Scholar
  70. 70.
    Targan SR, Landers CJ, Yang H et al. Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn’s disease. Gastroenterology 2005;128:2020–8.PubMedCrossRefGoogle Scholar
  71. 71.
    Fuchizaki U, Machi T, Kaneko S. Clinical challenges and images in GI. Yersinia enterocolitica mesenteric adenitis and terminal ileitis. Gastroenterology 2006;131:1379, 1659.PubMedCrossRefGoogle Scholar
  72. 72.
    Tuohy AM, O’Gorman M, Byington C, Reid B, Jackson WD. Yersinia enterocolitis mimicking Crohn’s disease in a toddler. Pediatrics 1999;104:e36.PubMedCrossRefGoogle Scholar
  73. 73.
    Meyer AM, Ramzan NN, Loftus EV, Jr., Heigh RI, Leighton JA. The diagnostic yield of stool pathogen studies during relapses of inflammatory bowel disease. J Clin Gastroenterol 2004;38:772–5.PubMedCrossRefGoogle Scholar
  74. 74.
    Sands BE. Inflammatory bowel disease: past, present, and future. J Gastroenterol 2007;42:16–25.PubMedCrossRefGoogle Scholar
  75. 75.
    Behr MA, Schurr E. Mycobacteria in Crohn’s disease: a persistent hypothesis. Inflamm Bowel Dis 2006;12:1000–4.PubMedCrossRefGoogle Scholar
  76. 76.
    Chamberlin W, Ghobrial G, Chehtane M, Naser SA. Successful treatment of a Crohn’s disease patient infected with bacteremic Mycobacterium paratuberculosis. Am J Gastroenterol 2007;102:689–91.PubMedCrossRefGoogle Scholar
  77. 77.
    Sechi LA, Gazouli M, Sieswerda LE et al. Relationship between Crohn’s disease, infection with Mycobacterium avium subspecies paratuberculosis and SLC11A1 gene polymorphisms in Sardinian patients. World J Gastroenterol 2006;12:7161–4.PubMedGoogle Scholar
  78. 78.
    Baldassarre ME, Altomare MA, Fanelli M et al. Does calprotectin represent a regulatory factor in host defense or a drug target in inflammatory disease? Endocr Metab Immune Disord Drug Targets 2007;7:1–5.Google Scholar
  79. 79.
    Bjerke K, Halstensen TS, Jahnsen F, Pulford K, Brandtzaeg P. Distribution of macrophages and granulocytes expressing L1 protein (calprotectin) in human Peyer’s patches compared with normal ileal lamina propria and mesenteric lymph nodes. Gut 1993;34:1357–63.PubMedCrossRefGoogle Scholar
  80. 80.
    Roseth AG, Fagerhol MK, Aadland E, Schjonsby H. Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand J Gastroenterol 1992;27:793–8.PubMedCrossRefGoogle Scholar
  81. 81.
    Steinbakk M, Naess-Andresen CF, Lingaas E, Dale I, Brandtzaeg P, Fagerhol MK. Antimicrobial actions of calcium binding leucocyte L1 protein, calprotectin. Lancet 1990;336:763–5.PubMedCrossRefGoogle Scholar
  82. 82.
    Roseth AG, Schmidt PN, Fagerhol MK. Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Scand J Gastroenterol 1999;34:50–4.PubMedCrossRefGoogle Scholar
  83. 83.
    Tibble J, Teahon K, Thjodleifsson B et al. A simple method for assessing intestinal inflammation in Crohn’s disease. Gut 2000;47:506–13.PubMedCrossRefGoogle Scholar
  84. 84.
    Fagerberg UL, Loof L, Myrdal U, Hansson LO, Finkel Y. Colorectal inflammation is well predicted by fecal calprotectin in children with gastrointestinal symptoms. J Pediatr Gastroenterol Nutr 2005;40: 450–5.Google Scholar
  85. 85.
    Loftus EV, Jr. Objective measures of disease activity: alternatives to symptom indices. Rev Gastroenterol Disord 2007;7 Suppl 2:S8–S16.PubMedGoogle Scholar
  86. 86.
    Angriman I, Scarpa M, D’Inca R et al. Enzymes in feces: Useful markers of chronic inflammatory bowel disease. Clin Chim Acta 2007.Google Scholar
  87. 87.
    Tibble JA, Sigthorsson G, Foster R, Forgacs I, Bjarnason I. Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. Gastroenterology 2002;123: 450–60.Google Scholar
  88. 88.
    Carroccio A, Iacono G, Cottone M et al. Diagnostic accuracy of fecal calprotectin assay in distinguishing organic causes of chronic diarrhea from irritable bowel syndrome: a prospective study in adults and children. Clin Chem 2003;49:861–7.PubMedCrossRefGoogle Scholar
  89. 89.
    Bunn SK, Bisset WM, Main MJ, Golden BE. Fecal calprotectin as a measure of disease activity in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2001;32:171–7.PubMedCrossRefGoogle Scholar
  90. 90.
    Sugi K, Saitoh O, Hirata I, Katsu K. Fecal lactoferrin as a marker for disease activity in inflammatory bowel disease: comparison with other neutrophil-derived proteins. Am J Gastroenterol 1996;91:927–34.PubMedGoogle Scholar
  91. 91.
    Buderus S, Boone J, Lyerly D, Lentze MJ. Fecal lactoferrin: a new parameter to monitor infliximab therapy. Dig Dis Sci 2004;49:1036–9.PubMedCrossRefGoogle Scholar
  92. 92.
    Walker TR, Land ML, Kartashov A et al. Fecal lactoferrin is a sensitive and specific marker of disease activity in children and young adults with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007;44:414–22.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Jennifer Strople
    • 1
  • Benjamin D. Gold
  1. 1.Children’s Memorial HospitalChicagoUSA

Personalised recommendations